SceneRay Receives NMPA Approval for World-First DBS System Targeting Opioid Addiction
In a landmark development for the global neuromodulation market, the National Medical Products Administration (NMPA) has officially granted marketing approval to SceneRay Medical’s Implantable Deep Brain Stimulation (DBS) System. This authorization marks a transformative shift in psychiatric care, signalling the arrival of the world’s first invasive brain-computer interface (BCI) specifically designed to combat refractory opioid addiction.
Redefining the Frontiers of Neuromodulation
While DBS has long been the gold standard for movement disorders like Parkinson’s, SceneRay is pioneering its application within the realm of behavioural health. The system—comprising an implantable stimulator and high-precision electrode leads—targets the brain’s “addiction circuits” by delivering micro-pulses to the Nucleus Accumbens (NAc) and the Anterior Limb of the Internal Capsule (ALIC). By modulating these specific nodes, the device intervenes in the reward and impulse-control pathways, effectively suppressing cravings and restoring a patient’s cognitive autonomy.
Clinical Excellence: A Path to Permanent Recovery
The clinical implications of this approval are profound. Data indicates that patients utilizing the SceneRay system begin to demonstrate the proactive ability to refuse drugs within just 3 to 6 months of activation. Most notably, the therapy offers the potential for long-term neural “re-tuning”; evidence suggests that after 1.5 to 2 years of treatment, patients can maintain total abstinence even after the device is deactivated or removed, based on public available information.
Key Features at a Glance:
- Targeted Precision: Dual-node stimulation of the NAc and ALIC to address both pleasure-seeking and impulse-inhibition deficits.
- Individualized Care: Physicians can remotely and wirelessly optimize stimulation parameters, ensuring a bespoke treatment journey for every patient.
- Reversible & Physical: Unlike permanent surgical interventions, this provides a reversible, physical pathway for patients who have exhausted traditional pharmaceutical and psychological options.
A “0 to 1” Innovation
This launch represents more than just a new product; it is a successful convergence of neurosurgery, psychiatry, and advanced brain science. For the millions of individuals suffering from moderate-to-severe refractory addiction, SceneRay has delivered a critical “last line of defense,” filling a long-standing void in the medical device sector.
As SceneRay begins its commercial rollout, the global medical community watches closely. This breakthrough does not just offer a new tool for clinicians—it offers a new life for those previously deemed “untreatable.”